Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients
Study Identifier
P15-692
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete
Results Available
Statistical Analysis Plan
Available Language(s): English
Protocol
Available Language(s): English
Scientific Result Summary
Available Language(s): English
Study Details
Medical Condition
Study Drug
Phase
N/A
Sex
Female & Male
Age
18 - 99 Years
Protocol Summary
The objective of this study is to assess quality of life (QoL), skin pain, work productivity/activity and health related problems in Swedish patients with moderate to severe HS before and after 6 months treatment with Adalimumab. Participants will be treated in accordance with normal routine clinical care.
Study Locations
Location
Status
Location
Universitetssjukhuset Linköping
Linkoping, Västra Götaland County, Sweden, 581 85
Status
Not applicable
Location
Hallands Hospital Halmstad
Halmstad, Sweden, 301 85
Status
Not applicable
Location
Blekinge Hospital
Karlskrona, Sweden, SE-37185
Status
Not applicable
Location
Skaraborgs Hospital
Skövde, Sweden, 541 85
Status
Not applicable
Location
Karolinska Univ Sjukhuset
Solna, Sweden, 17176
Status
Not applicable
Location
Kungsholmens Hudklinik
Stockholm, Sweden, 112 51
Status
Not applicable
Showing {first} - {last} of {total} Results